CTropMed EXAM STUDY GUIDE
Naegleria fowleri treatment - ANSWER Amphoterecin B
Miltefosine
Rifampin
Voriconazole
Onchocerciasis effects - ANSWER All parts of the eye except the lens
Treatment for cutaneous leishmaniasis - ANSWER IV SSG
Antimony
Imiquimod
Paromomycin
Cryo/thermotherapy
Vector for leishmaniasis - ANSWER Sand flies
New world: Lutzomyia
Old world: Phlebotomus
Max incubation of Ebola - ANSWER 21 days
Gnathostomiasis manifestations - ANSWER Nonspecific for a few weeks
≥1 month after innoculation: mobile subcutaneous mass
(larger than CLM, earlier than Calabar swellings)
SAM w/ shock management - ANSWER 15 ml/kg of D5 ½ NS or D5 ½ LR
over 1 hour
Acute mountain sickness threshold - ANSWER Risk rapidly increases at:
8000 feet
2500 meters
Tetanus types - ANSWER Classic (begins at jaw and generalizes)
Local (muscle contraction around a wound)
Cephalic (otitis, cranial nerve paralysis)
, Typhus: species, distribution and vector (3) - ANSWER Murine: R. typhi,
flea/rodent, worldwide
Epidemic: R. prowazekii, louse, global South
Scrub: O. tsutsugamushi, mites, Asia (eschar)
Bacteria with Schisto - ANSWER Salmonella
Rabies PEP (U.S.) - unvaccinated - ANSWER RIG and 4 doses of vaccine over
14 days
Rabies PEP (U.S.) - vaccinated - ANSWER 2 doses of vaccine over 3 days
Loa loa vector - ANSWER Horse flies (Chrysops)
Species causing lymphatic filariasis (3) - ANSWER Wuchereria bancrofti
Brugia malayi
Brugia timori
Trench fever agent and vector - ANSWER Bartonella quintana (humans are
only reservoir)
Body louse
Mefloquine timing - ANSWER 2-3 weeks prior
1 week after
Toxocara: most common presentation by age - ANSWER Young: VLM
Older children / adults: OLM
Japanese encephalitis risk - ANSWER More time in endemic area increases
risk
Japanese encephalitis manifestations - ANSWER Lower extremity spastic
paralysis (+ seizure, neck stiffness, fever, etc.)
Inflammation of grey matter (no white)
Blood phase of T. cruzi - ANSWER Trypomastigote
Naegleria fowleri treatment - ANSWER Amphoterecin B
Miltefosine
Rifampin
Voriconazole
Onchocerciasis effects - ANSWER All parts of the eye except the lens
Treatment for cutaneous leishmaniasis - ANSWER IV SSG
Antimony
Imiquimod
Paromomycin
Cryo/thermotherapy
Vector for leishmaniasis - ANSWER Sand flies
New world: Lutzomyia
Old world: Phlebotomus
Max incubation of Ebola - ANSWER 21 days
Gnathostomiasis manifestations - ANSWER Nonspecific for a few weeks
≥1 month after innoculation: mobile subcutaneous mass
(larger than CLM, earlier than Calabar swellings)
SAM w/ shock management - ANSWER 15 ml/kg of D5 ½ NS or D5 ½ LR
over 1 hour
Acute mountain sickness threshold - ANSWER Risk rapidly increases at:
8000 feet
2500 meters
Tetanus types - ANSWER Classic (begins at jaw and generalizes)
Local (muscle contraction around a wound)
Cephalic (otitis, cranial nerve paralysis)
, Typhus: species, distribution and vector (3) - ANSWER Murine: R. typhi,
flea/rodent, worldwide
Epidemic: R. prowazekii, louse, global South
Scrub: O. tsutsugamushi, mites, Asia (eschar)
Bacteria with Schisto - ANSWER Salmonella
Rabies PEP (U.S.) - unvaccinated - ANSWER RIG and 4 doses of vaccine over
14 days
Rabies PEP (U.S.) - vaccinated - ANSWER 2 doses of vaccine over 3 days
Loa loa vector - ANSWER Horse flies (Chrysops)
Species causing lymphatic filariasis (3) - ANSWER Wuchereria bancrofti
Brugia malayi
Brugia timori
Trench fever agent and vector - ANSWER Bartonella quintana (humans are
only reservoir)
Body louse
Mefloquine timing - ANSWER 2-3 weeks prior
1 week after
Toxocara: most common presentation by age - ANSWER Young: VLM
Older children / adults: OLM
Japanese encephalitis risk - ANSWER More time in endemic area increases
risk
Japanese encephalitis manifestations - ANSWER Lower extremity spastic
paralysis (+ seizure, neck stiffness, fever, etc.)
Inflammation of grey matter (no white)
Blood phase of T. cruzi - ANSWER Trypomastigote